Borgersen v. Cardiovascular Systems, Inc.

729 N.W.2d 619, 2007 Minn. App. LEXIS 39, 2007 WL 968867
CourtCourt of Appeals of Minnesota
DecidedApril 3, 2007
DocketA06-710
StatusPublished
Cited by7 cases

This text of 729 N.W.2d 619 (Borgersen v. Cardiovascular Systems, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Borgersen v. Cardiovascular Systems, Inc., 729 N.W.2d 619, 2007 Minn. App. LEXIS 39, 2007 WL 968867 (Mich. Ct. App. 2007).

Opinion

OPINION

HUDSON, Judge.

On appeal from summary judgment dismissing his claims for breach of an employment contract and unlawful termination under Minn.Stat. § 181.932, subd. 1(a) (2004), appellant argues that (1) the district court erred by concluding that he did not make a “report” within the meaning of Minn.Stat. § 181.932, subd. 1(a); (2) the parol-evidence rule precluded the district court from considering the cover letter in interpreting the employment agreement because the employment agreement contained an integration clause; and (3) there remain issues of material fact which preclude summary judgment. We affirm in part, reverse in part, and remand.

FACTS

In December 2002, respondent Cardiovascular Systems, Inc. (CSI) hired appellant Svenn Borgersen as Director of Engineering Analysis and Design. Borgerson’s duties included product development, developing test protocols, conducting laboratory testing (known as “bench testing”), and preparing test results. When it offered appellant the job, CSI sent him two documents: a cover letter and an employment agreement. The cover letter reads, in relevant part:

This letter and the enclosed Employment Agreement summarize our understanding of the terms of your employment and provide you the means to accept our offer as described. Upon acceptance of this offer and your active start of employment, you will become an “at will” employee of [CSI]. This means that you will be free to resign at any time. Likewise, [CSI] will have the right to terminate your employment at any time with or without reason or notice. Acceptance of this offer acknowledges your understanding and acceptance of the “at will” nature of your employment.
Please indicate your acceptance of this offer of employment and agreement with the terms described in the enclosed document by signing and returning all enclosed paperwork to the address indicated below.

The cover letter was signed only by the CEO of CSI.

The employment agreement, which was signed by both the CEO of CSI and appellant, states that the employment shall “continue until terminated by either party as provided for hereunder” and lists “with cause,” “death,” “disability,” and “dissolution of the corporation” as possible reasons for termination. In contrast to the “at-will” language in the cover letter, the “with cause” provision of the employment agreement provides as follows:

Notwithstanding anything contained herein to the contrary, the Corporation, *622 acting by and through the Board of Directors, shall have the right to immediately terminate Employee’s employment under this Agreement for “Cause,” which shall mean: (i) the willful and continued failure by Employee to substantially perform Employee’s duties with the Corporation; or (ii) the willful engaging by Employee in conduct which is demonstrably and materially in the opinion of the Board injurious to the Corporation, monetarily or otherwise.

The employment agreement also includes an integration clause:

This agreement embodies the entire agreement and understanding among the parties relative to subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter.

The employment agreement also includes a modification clause, which provides: “This Agreement shall not be modified or amended except by a written instrument signed by the parties.”

At all times relevant to this case, CSI was involved in the research, design, development, and eventual sale of a product known as the orbital atherectomy device (“OAD”). The OAD is a gas-powered, mechanical device designed to be used by cardiologists to remove tissue blockages from stents in human arteries and in peripheral arteries and veins. In February 2004, CSI submitted an application to the Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to conduct human trials of the OAD. Because bench testing must be conducted on devices such as the OAD before the device is tested on humans, in March 2004, the FDA requested additional information and “bench testing which demonstrates the possible interaction between [the device] and stents under worst-case conditions.”

In April or May 2004, in response to the FDA’s request, tests were conducted, which appellant claims resulted in “catastrophic failures” of the device. 1 Appellant argues that the experimental procedures used “were perfectly representative of what was going on with the device to be used in the human body.” As a result, appellant was concerned about the safety of the device and reported the results of the experiments to his supervisors at CSI. To one supervisor he said: “Do you know what would happen if this was shown to the FDA? This could kill a patient, could kill an animal.” These statements to his supervisors are what appellant believes led to his termination and what he argues constitute a protected “report” under Minn.Stat. § 181.932.

In May 2004, CSI submitted a report on the OAD to the FDA; it did not include information about the initial “catastrophic failures” of the device.

CSI claimed that it was not satisfied with appellant’s work, and on approximately May 24, 2004, CSI fired appellant. On July 22, 2004, appellant contacted a compliance officer at the FDA by e-mail to express his concerns about CSI’s IDE application and the safety of CSI’s device. The e-mail detailed appellant’s belief that information regarding the “potentially deadly design and performance aspects of the current device” had “been deliberately withheld” from the FDA.

On October 1, 2004, appellant filed a complaint in the Hennepin County district court alleging that CSI breached the em *623 ployment agreement because the agreement provided that he could only be terminated “for cause.” Appellant also alleged that CSI violated Minn.Stat. § 181.932, subd. 1(a) by firing him in retaliation for good-faith reports he made with respect to CSI’s failure to comply with FDA regulations requiring disclosure of the risks associated with the device.

CSI moved for summary judgment. The district court issued an order granting CSI’s motion for summary judgment and dismissing appellant’s claims with prejudice. In its order, the district court concluded that the cover letter was part of the employment agreement, that CSI had the right to terminate appellant at will, and that there were no genuine issues of material fact with respect to the breach-of-contract claim. The district court also concluded that appellant had not made a “report” within the meaning of Minn.Stat. § 181.932, subd. 1(a) and, as a matter of law, appellant could not sustain his whis-tleblower claim. This appeal follows.

The Minnesota Chapter of the National Employment Lawyers Association, writing as amicus curiae, submitted a brief arguing that protection under Minn.Stat. § 181.932 is not limited to reports of past acts. It also argues that the district court’s decision contravenes the policy of protecting public safety, which underlies the Whistleblower Act.

ISSUES

I.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Petra Brokken v. Hennepin County
140 F.4th 445 (Eighth Circuit, 2025)
Becker v. Jostens, Inc.
210 F. Supp. 3d 1110 (D. Minnesota, 2016)
Arrow Southampton, LLC v. Jeremiah Akinnola
Court of Appeals of Minnesota, 2016
Maday v. Grathwohl
805 N.W.2d 285 (Court of Appeals of Minnesota, 2011)
Reiter v. Recall Corp.
542 F. Supp. 2d 945 (D. Minnesota, 2008)
Taylor v. Lifetouch National School Studios, Inc.
490 F. Supp. 2d 944 (N.D. Indiana, 2007)
GRUNDTNER v. University of Minnesota
730 N.W.2d 323 (Court of Appeals of Minnesota, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
729 N.W.2d 619, 2007 Minn. App. LEXIS 39, 2007 WL 968867, Counsel Stack Legal Research, https://law.counselstack.com/opinion/borgersen-v-cardiovascular-systems-inc-minnctapp-2007.